Study Evaluating Safety Of BMP-655/ACS As An Adjuvant Therapy For Rotator Cuff Repair

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Rotator Cuff Tear

Treatments: Biological: BMP-655/ACS or Standard of Care

Study type: Interventional

Funder types: Industry

Identifiers

NCT00936559

3202V1-1001

Details and patient eligibility

About

Study to assess the safety of 3 differing concentrations of BMP-655/ACS in subjects with full thickness Rotator Cuff Tears (RCTs).

Full description

This decision to terminate enrollment in this study is based on the company's change in prioritization for the portfolio and was not due to any safety concerns, or regulatory interactions.

Patients already enrolled in the study, should continue to complete assessments as described in the protocol.

Enrollment: 13 patients

Sex: All

Ages: 25 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male subjects and surgically sterile or postmenopausal female subjects between the ages of 25 and 75 years old with specific full-thickness RCTs identified on closed MRI within 3 months before surgery.

Exclusion criteria

• Subjects who have had previous surgical intervention to the shoulder joint under study or additional injury requiring surgical repair or a history of shoulder dislocation in the affected shoulder or physical examination findings of instability in either shoulder
• Subjects who are unable to complete functional evaluations because of any other concurrent injuries or impairment in either the arm
• Subjects identified with specific fatty infiltration of their RC muscles on MRI taken within 3 months prior to surgical repair
• Subjects with moderate or severe degenerative arthritis of the shoulder under study or any bone abnormalities as confirmed on a radiograph
• Subjects with rheumatologic conditions affecting the shoulder joints or autoimmune disorders, treated with more than 3 corticosteroid injections in the shoulder under study within 1 year of planned surgery, any recent corticosteroid injection in the shoulder or currently receiving oral corticosteroids
• Subjects who are either unwilling or unable to undergo examination with closed MRI.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

13 participants in 3 patient groups

1

Experimental group

Description:

Arm A

Treatment:

Biological: BMP-655/ACS or Standard of Care

Biological: BMP-655/ACS or Standard of Care

Biological: BMP-655/ACS or Standard of Care

2

Experimental group

Description:

Arm B

Treatment:

Biological: BMP-655/ACS or Standard of Care

Biological: BMP-655/ACS or Standard of Care

Biological: BMP-655/ACS or Standard of Care

3

Experimental group

Description:

Arm C

Treatment:

Biological: BMP-655/ACS or Standard of Care

Biological: BMP-655/ACS or Standard of Care

Biological: BMP-655/ACS or Standard of Care